MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) has moved to maximise enterprise value for shareholders with the appointment of UK capital markets advisory company Hannam & Partners as financial and corporate advisors.
MXC says Hannam & Partners is a highly regarded UK advisory firm with a long track record in UK capital markets, and more recently in the UK and EU cannabis sector.
MGC Pharmaceuticals has also made some changes to its executive team and board, transitioning to a corporate structure more in line with those of UK-listed companies.
Changes to management
The company has appointed Yifat Steuer, who was previously engaged as an advisor to the executive team, as chief operating officer and deputy CEO.
Steuer has more than 20 years of experience as an executive, working across a range of pharmaceutical companies including Johnson & Johnson (NYSE:JNJ) and GlaxoSmithKline, as well as experience working with small and medium enterprises (SMEs) and start-ups.
She is a qualified Chartered Accountant and holds a MBA degree from Bayes Business School – University of London.
Steuer will work closely with CEO Roby Zomer to execute on MGC Pharma’s business strategy, leveraging her experience in pharmaceuticals, manufacturing, logistics, medical technology and digital health.
Brett Mitchell, chair of MXC, has also transitioned to a non-executive position in line with market expectations and will continue to provide corporate and capital markets advisory services to the company through an existing consultancy agreement with his private consulting company.